Clinical trial
OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid…
NCT00105937 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00105937 |
|---|---|
| Title | OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients |
| Official title | Multi-center, Open Label, Long-term Study of OraVescent Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pain, Cancer |
| Intervention type | Drug |
| Interventions | OraVescent fentanyl citrate |
| Enrollment | 300 |
| Start date | Apr 1, 2004 |
| Completion | Nov 1, 2006 |
| First posted | Mar 21, 2005 |
| Last update posted | Jun 29, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: